Log in to save to my catalogue

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal ade...

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal ade...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4780258

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma

About this item

Full title

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2016-03, Vol.22 (3), p.278-287

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Expression of HNF1A and KRT81 stratifies pancreatic ductal adenocarcinoma tumors into different subtypes, and expression of cytochrome P450 3A5 mediates basal and/or drug-induced therapy resistance in each subtype.
Although subtypes of pancreatic ductal adenocarcinoma (PDAC) have been described, this malignancy is clinically still treated as a s...

Alternative Titles

Full title

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4780258

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4780258

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/nm.4038

How to access this item